Swiss pharmaceutical giant Novartis announced Monday that European regulators have granted approval for Rhapsido, a new oral medication targeting chronic spontaneous urticaria (CSU), a condition that causes persistent hives.
The European Commission’s approval on April 27 marks a significant milestone for patients suffering from this chronic skin disorder. According to the pharmaceutical company, this represents a breakthrough in treatment options.
“Rhapsido is the first oral targeted treatment approved for CSU, offering a unique approach to CSU treatment in a pill taken twice daily without any lab monitoring required,” the company said in a statement.
The new medication provides patients with a convenient treatment option that doesn’t require regular laboratory testing, potentially improving quality of life for those dealing with chronic hives symptoms.
